Overview
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
Status:
Terminated
Terminated
Trial end date:
2006-05-01
2006-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
NICHD Neonatal Research NetworkCollaborator:
National Center for Research Resources (NCRR)Treatments:
Nitric Oxide
Criteria
Inclusion Criteria- Any infant with a birth weight 401 - 1500 grams and < 34 weeks gestational age with an
OI (mean Paw x FiO2 x 100/PaO2) > 10 on two consecutive blood gases at least 30
minutes apart, but no more than 12 hours apart.
or
- Infants > 1500 grams and < 34 weeks gestational age will be entered in the Larger
Preemie Pilot Study if they have an OI greater than or equal to 15 on two consecutive
blood gases at least 30 minutes apart, but no more than 12 hours apart.
- Infants requiring assisted ventilation with a diagnosis of RDS/HMD, pneumonia and/or
sepsis, aspiration syndrome, idiopathic pulmonary hypertension, or suspected pulmonary
hypoplasia associated with PROM and/or oligohydramnios.
- Greater than or equal to 4 hours after one dose of surfactant.
- Less than or equal to 120 hours of age.
- All infants must have an indwelling arterial line.
Exclusion Criteria
- Any infant in whom a decision has been made not to provide full treatment (e.g.
chromosomal anomalies or severe birth asphyxia).
- Known structural congenital heart disease, except patent ductus arteriosus and
atrial-level shunts.
- Infants with any major abnormality involving the respiratory system such as congenital
diaphragmatic hernia, tracheoesophageal fistula or cystic fibrosis.
- Any bleeding diathesis considered to be clinically significant or thrombocytopenia
with platelet count < 50,000.
- Prior enrollment into a conflicting clinical trial such as the Neonatal Network
Surfactant CPAP trial.Inclusion Criteria